Please assess the completion status of the following clinical trial:

Trial Title: Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Have type 2 diabetes mellitus (World Health Organization \[WHO\] Classification of Diabetes)~* Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m\^2)~* Have Glycated Hemoglobin A1c (HbA1c) ≥7.5% and ≤12.0%, as measured by the central laboratory at entry~* Current U-100 insulin/analogue users on \>200 and ≤600 units per day for ≥3 months at study entry and reconfirmed at randomization~* Have a history of stable body weight for at least 3 months prior to study entry~* Concomitant medications may include metformin (MET), dipeptidyl peptidase-4 (DPP-4) inhibitors approved for use with insulin at time of study entry (for example, sitagliptin, saxagliptin, and linagliptin), pioglitazone, and/or sulfonylureas (SUs)/glinides (repaglinide or nateglinide). Participant's oral antihyperglycemic drug (OAD) dose(s) must have been stable for ≥3 months~Major Exclusion Criteria:~* Have type 1 diabetes mellitus or other types of diabetes mellitus apart from type 2 diabetes mellitus~* Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransferase or aspartate aminotransferase levels ≥3 times the upper limit of the reference range~* Have chronic kidney disease stage 4 and higher or history of renal transplantation~* Have history of more than 1 episode of severe hypoglycemia within the 6 months prior to study entry~* Have received insulin by continuous subcutaneous insulin infusion in the 3 months prior to study entry~* Have received U-500R in the 3 months prior to study entry~* Have had a blood transfusion or severe blood loss within 3 months prior to study entry or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia~* Are taking chronic systemic glucocorticoid therapy or have received such therapy within the 4 weeks immediately prior to study entry~* Have an irregular sleep/wake cycle~* Have used rosiglitazone, once- or twice-daily glucagon-like peptide-1 (GLP-1) receptor agents, pramlintide, or other injectable or oral antihyperglycemic therapy not listed in the inclusion criteria in the 3 months prior to study entry. Participants may not have used once-weekly GLP-1 receptor agents in the 4 months prior to study entry~* Have used any weight loss drugs in the 3 months prior to study entry~* Have a history of bariatric surgery~* Have a history of malignancy other than basal cell or squamous cell skin cancer~* Have New York Heart Association (NYHA) Class III or IV per NYHA Cardiac Disease Functional Classification~* Are breastfeeding or pregnant, or intend to become pregnant during the course of the study, or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Human Regular U-500 Insulin TID (Type: EXPERIMENTAL): Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.
- Human Regular U-500 Insulin BID (Type: EXPERIMENTAL): U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).